OTCM
TOMDF
Market cap1kUSD
Apr 04, Last price
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name
Todos Medical Ltd
Chart & Performance
Profile
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||
Revenues | 7,695 -37.08% | |||||||
Cost of revenue | 4,005 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | 3,690 | |||||||
NOPBT Margin | 47.95% | |||||||
Operating Taxes | 13 | |||||||
Tax Rate | 0.35% | |||||||
NOPAT | 3,677 | |||||||
Net income | (24,994) -66.64% | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 700 | |||||||
BB yield | -5.52% | |||||||
Debt | ||||||||
Debt current | 5,301 | |||||||
Long-term debt | 33,047 | |||||||
Deferred revenue | 46 | |||||||
Other long-term liabilities | 226 | |||||||
Net debt | 37,819 | |||||||
Cash flow | ||||||||
Cash from operating activities | (2,713) | |||||||
CAPEX | (74) | |||||||
Cash from investing activities | (1,807) | |||||||
Cash from financing activities | 4,365 | |||||||
FCF | 10,103 | |||||||
Balance | ||||||||
Cash | 34 | |||||||
Long term investments | 495 | |||||||
Excess cash | 144 | |||||||
Stockholders' equity | (110,708) | |||||||
Invested Capital | 114,392 | |||||||
ROIC | 3.51% | |||||||
ROCE | 92.27% | |||||||
EV | ||||||||
Common stock shares outstanding | 1,425,643 | |||||||
Price | 0.01 -84.77% | |||||||
Market cap | 12,688 -68.06% | |||||||
EV | 51,129 | |||||||
EBITDA | 4,440 | |||||||
EV/EBITDA | 11.52 | |||||||
Interest | 14,850 | |||||||
Interest/NOPBT | 402.44% |